What is the current market price of pitubrutinib/pitobrutinib? How to buy

Pirtobrutinib has been launched in China before, but it has not yet been included in the medical insurance system, so the purchase cost is relatively high. Clinically, it is mainly used to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL), as well as patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least two lines of therapy (including BTK inhibitors and BCL-2 inhibitors). The drug inhibits B cell proliferation and survival by blocking the BTK signaling pathway, providing new treatment options for refractory patients.

In the domestic market, the common specifications of Pitobrutinib are100 mg, 14 tablets and 4 tablets, with each box selling for about RMB 40,000. Due to the high price, patients usually need to fully consult a hematologist before purchasing and taking medication, and develop a treatment plan based on the severity of the disease and economic conditions. The price of original drugs in overseas markets is higher. In the United States and Europe, specifications such as 50mg 30 tablets or 100mg 60 tablets can cost close to 100,000 yuan per box, reflecting the differences in international drug research and development and market pricing. For most patients, long-term medication costs are high, so treatment benefits need to be weighed against affordability.

It is worth noting that generic versions of pitubrutinib have appeared overseas, and the drug ingredients are basically the same as the original drug. For example, the 50mg*30 tablets produced by a Lao pharmaceutical factory may be sold for more than 2,000 yuan per box, which reduces the cost of medication for patients. When purchased through legal channels, these generic drugs can provide accessible options for patients with limited financial resources while ensuring the clinical efficacy of the drugs. When choosing generic drugs, patients should pay attention to the formality of the source of the drug, consistency of ingredients, and production qualifications to ensure drug safety and efficacy.

In general, pitubrutinib has clear clinical value in the treatment of relapsed or refractory MCL and CLL/SLL. Whether it is an original drug or a generic drug, it provides an important treatment option for high-risk patients.

Reference materials:https://go.drugbank.com/drugs/DB17472